Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A post marketing pediatric study of KEDRAB®[Rabies Immune Globulin (Human)]

Next Previous
Trial Profile

A post marketing pediatric study of KEDRAB®[Rabies Immune Globulin (Human)]

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 24 Aug 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 19 Aug 2020 According to an Kamada, Kedrion Biopharma media release, the Study Met its Primary Objective, which was to Confirm the Safety of KEDRAB in the Pediatric Population.
  • 19 Aug 2020 Results published in a Kamada, Kedrion Biopharma media release.
  • 19 Aug 2020 According to an Kamada, Kedrion Biopharma media release, the trial was conducted at two sites, one in Arkansas and another in Rhode Island. The study included 30 pediatric patients (ages 0-17 years old), each of whom received KEDRAB as part of PEP treatment following exposure or suspected exposure to an animal suspected or confirmed to be rabid, and safety follow-up was conducted for up to 84 days.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top